flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has received a €2.5 million grant from Flanders Innovation and Entrepreneurship (VLAIO). This grant will be used to examine the role and therapeutic potential of proteins involved in regulating localized release of transforming growth factor beta (TGF-beta).
So hot it hurts - Leuven researchers uncover ion channel trio that mediates painful heat sensing
Researchers at VIB & KU Leuven have uncovered a trio of complementary ion channels in sensory neurons that mediate detection of acute, harmful heat. Having three redundant molecular heat-sensing mechanisms provides a powerful fail-safe mechanism that protects against burn injuries. The seminal findings have been published today in Nature.
Biocartis Selected for Oral Presentation at Cancer Research Meeting
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that a study abstract on the analytical and clinical validation of the liquid biopsy Idylla(TM) ctKRAS and ctNRAS-BRAF Tests has been selected for oral presentation at the renowned AACR (American Association for Cancer Research) Annual Meeting in Chicago (US), taking place between 14-18 April 2018. Results demonstrated that the Idylla(TM) ctKRAS and ctNRAS-BRAF Mutation Tests provide a sensitive, reliable and fast solution for liquid biopsy RAS-BRAF ctDNA (circulating tumor) testing, and that RAS-BRAF mutation status can be adequately determined using blood plasma from metastatic colorectal cancer (mCRC) patients with liver metastases.
VIB Plant-derived volatiles may serve as future antifungals
A research team at the VIB-KU Leuven Center for Microbiology has developed a novel screening method to identify antimicrobial properties of volatile substances. With this assay, they tested the vapour-phase-mediated activity of 175 essential oils (EOs) and 37 EO components. Approximately half of them proved active against the most drug-resistant type of Candida. In a context of fungi showing increasing drug resistance, these findings may be useful in both medical and agricultural applications.